The historical rank and industry rank for PhoenixBio Co's Pretax Margin % or its related term are showing as below:
TSE:6190'
s Pretax Margin % Range Over the Past 10 Years
Min: -31.86 Med: -23.06 Max: 24.04
Current: 8.4
TSE:6190's Pretax Margin % is ranked better than 78.68% of 938
companies
in the Biotechnology industry
Industry Median: -89.895
vs TSE:6190: 8.40
PhoenixBio Co (TSE:6190) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
PhoenixBio Co Pretax Margin % Related Terms
PhoenixBio Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for PhoenixBio Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6190 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, PhoenixBio Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhoenixBio Co (TSE:6190) has a Pretax Margin % of 14.22% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PhoenixBio Co and its competitors. According to the industry distribution chart, PhoenixBio Co ranks #200 out of 938 companies in the Biotechnology industry, placing it in the top 21.3%.
Is PhoenixBio Co's Pretax Margin % too high?
PhoenixBio Co's current Pretax Margin % is 14.22%. Based on the distribution chart, PhoenixBio Co ranks #200 out of 938 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PhoenixBio Co has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #200 out of 938 companies for Pretax Margin %. This places PhoenixBio Co in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PhoenixBio Co and its competitors. PhoenixBio Co's current Pretax Margin % is 14.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円359.09, compared to a current price of 円344.00 — trading 4.2% below its estimated fair value. The current Pretax Margin % is 14.22%. PhoenixBio Co's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Pretax Margin % is 14.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円344.00 is trading 4.2% below its estimated GF Value™ of 円359.09.
GuruFocus considers PhoenixBio Co to be Fairly Valued.
Key valuation signals for TSE:6190:
Pretax Margin %: 14.22%
GF Value™: 円359.09 vs. price of 円344.00 (4.2% below fair value)
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
57GF Score
Get the complete analysis for TSE:6190
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
